Summary of findings 14. Paroxetine compared with nefazodone for depression.
| Paroxetine compared with nefazodone for depression | ||||||
| Patient or population: patients with depression Settings: in‐ and out‐patients Intervention: paroxetine Comparison: nefazodone | ||||||
| Outcomes | Illustrative comparative risks* (95% CI) | Relative effect (95% CI) | No of Participants (studies) | Quality of the evidence (GRADE) | Comments | |
| Assumed risk | Corresponding risk | |||||
| Nefazodone | Paroxetine | |||||
| Failure to respond at endpoint (6‐12 weeks) | 450 per 1000 | 202 per 1000 (54 to 506) | OR 0.31 (0.07 to 1.25) | 40 (1 study) | ⊕⊕⊕⊝ moderate1 | |
| Failure to respond at 1‐4 weeks | See comment | See comment | Not estimable | 0 (0) | See comment | No trial reported this outcome. |
| Failure to respond at 16‐24 weeks | Study population | OR 0.64 (0.17 to 2.38) | 40 (1 study) | ⊕⊕⊕⊝ moderate1 | ||
| 400 per 1000 | 299 per 1000 (102 to 613) | |||||
| Moderate | ||||||
| Failure to remit at endpoint | Not estimable | 0 (0) | ||||
| SMD at endpoint | The mean SMD at endpoint in the intervention groups was 0.12 standard deviations lower (0.37 lower to 0.14 higher) | 235 (2 studies) | ⊕⊕⊕⊝ moderate1 | The point estimate of the effect size corresponds to a small effect according to Cohen 1992. | ||
| Failure to complete ‐ any cause ‐ | 250 per 1000 | 150 per 1000 (35 to 464) | OR 0.53 (0.11 to 2.60) | 40 (1 study) | ⊕⊕⊕⊝ moderate1 | |
| Participants with at least some Side Effects | 838 per 1000 | 781 per 1000 (638 to 879) | OR 0.69 (0.34 to 1.40) | 206 (1 study) | ⊕⊕⊕⊝ moderate1 | |
| *The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; SMD: standardized mean difference; OR: Odds ratio; | ||||||
| GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate. | ||||||
1 Blinding stated but not tested. No information on randomisation procedures and allocation concealment.